Analyst Ratings For BioTelemetry (NASDAQ:BEAT)
Today, Benchmark Co. raised its price target on BioTelemetry (NASDAQ:BEAT) to $44.00 per share.
There are 5 buy ratings on the stock.
The current consensus rating on BioTelemetry (NASDAQ:BEAT) is Buy (Score: 3.00) with a consensus target price of $39.50 per share, a potential 13.83% upside.
Some recent analyst ratings include
- 7/14/2017-Lake Street Capital Reiterated Rating of Buy.
- 12/13/2016-Gabelli Reiterated Rating of Buy.
- 9/13/2016-Sidoti initiated coverage with a Buy rating.
Recent Insider Trading Activity For BioTelemetry (NASDAQ:BEAT)
BioTelemetry (NASDAQ:BEAT) has insider ownership of 9.60% and institutional ownership of 79.75%.
- On 5/15/2017 Robert J. Rubin, Director, sold 15,000 with an average share price of $28.14 per share and the total transaction amounting to $422,100.00. View SEC Filing
- On 3/20/2017 Fred Broadway, SVP, sold 3,429 with an average share price of $26.90 per share and the total transaction amounting to $92,240.10. View SEC Filing
- On 2/27/2017 George Hrenko, SVP, sold 126,043 with an average share price of $25.95 per share and the total transaction amounting to $3,270,815.85. View SEC Filing
- On 2/21/2017 Fred Broadway, SVP, sold 8,070 with an average share price of $24.81 per share and the total transaction amounting to $200,216.70. View SEC Filing
- On 9/19/2016 George Hrenko, SVP, sold 1,061 with an average share price of $18.50 per share and the total transaction amounting to $19,628.50. View SEC Filing
- On 9/13/2016 Heather C Getz, CFO, sold 5,866 with an average share price of $18.23 per share and the total transaction amounting to $106,937.18. View SEC Filing
- On 9/13/2016 Joseph H Capper, Insider, sold 26,847 with an average share price of $18.23 per share and the total transaction amounting to $489,420.81. View SEC Filing
Recent Trading Activity for BioTelemetry (NASDAQ:BEAT)
Shares of BioTelemetry closed the previous trading session at 34.85 up +0.15 0.43% with 342,693 shares trading hands.